-
Clinical Trials & Development4 days agoESMO 2026: Amgen’s Imdelltra slashes death risk by nearly 60% in small cell lung cancer
When used alongside AstraZeneca’s Imfinzi, the bispecific T cell engager Imdelltra extended survival by eight months versus Imfinzi alone in Phase 3 study testing the combo...
-
Clinical Trials & Development4 days agoSTAT+: Incyte pancreatic cancer medicine induces lasting tumor responses, company says at ESMO
A targeted drug from Incyte, when used in combination with chemotherapy, induced lasting tumor responses in certain patients with pancreatic cancer.
-
Clinical Trials & Development4 days agoMS has plenty of drugs. This Ocrevus veteran sees what’s missing.
After helping launch a blockbuster Roche and Genentech therapy, Erik Lundgren is betting that Immunic's experimental drug can address persistent gaps in MS care, with pivotal...
-
Clinical Trials & Development4 days agoGenmab’s ADC beats survival expectations in Phase 3 ovarian cancer trial
Extending both progression-free and overall survival, Genmab’s Rina-S “sets a high bar for future competition” in a market served by AbbVie, analysts said.
-
Clinical Trials & Development4 days agoSTAT+: Moderna CEO on what’s next after success in cancer vaccine
Moderna's CEO Stéphane Bancel on what's next after the recent success of a cancer vaccine, and how that impacts the company's business strategy.
-
Clinical Trials & Development4 days agoSTAT+: Moderna CEO on what’s next after success in cancer vaccine
Moderna's CEO Stéphane Bancel on what's next after the recent success of a cancer vaccine, and how that impacts the company's business strategy.
-
Clinical Trials & Development4 days agoEledon Pharmaceuticals Presents Phase 2 BESTOW Trial Data Showing Sustained Improvements in Quality of Life and Symptom Burden with Tegoprubart Compared to Tacrolimus
IRVINE, Calif., Oct. 26, 2026 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) today announced new positive patient-reported outcomes data from the Phase 2 BESTOW...
-
Clinical Trials & Development4 days ago
Genentech’s Divarasib Demonstrated Best-In-Class Efficacy, Advancing the Standard of Care in Previously Treated KRAS G12C-Mutated Lung Cancer
South San Francisco, CA -- October 25, 2026 -- Genentech, a member of the Roche Group (SIX: RO, ROP; OTCQX: RHHBY), announced today pivotal results from...
-
Clinical Trials & Development4 days ago
Johnson & Johnson Reports 75% Tumor Response Rate in Advanced Prostate Cancer with JNJ-6143, a First-in-Class RIPTAC™ Molecule
New Brunswick, N.J. October 25, 2026 /PR Newswire/ – Johnson & Johnson (NYSE:JNJ) today announced promising Phase 1 results for JNJ-6143 (formerly HLD-0915), an investigational once-daily...
-
Clinical Trials & Development5 days ago
BioNTech and Bristol Myers Squibb Report Encouraging Global Phase 2 data for Pumitamig in Advanced NSCLC After Progression on Immunotherapy Plus Chemotherapy
MAINZ, Germany, and PRINCETON, USA, October 25, 2026 – BioNTech SE (Nasdaq: BNTX, “BioNTech”) and Bristol Myers Squibb Company (NYSE: BMY, “BMS”) today announced first data...
LncRNA SBF2-AS1 Worsens Heart Injury After Attack via miR-149-5p/PHLPP2 Axis
Stigmatizing language found in over half of primary care patient records
Research report: The Influence of Renal or Hepatic Impairment on the Pharmacokinetics of Iclepertin (BI 425809): Results from Two Phase I Open-Label, Non-randomised, Single Dose, Parallel Design Studies
Novartis buys Synnovation’s PI3Kα inhibitors for $3 billion
Novartis to pay $2B upfront to take next-gen PI3Kα inhibitor from Synnovation
